High-fat diet-induced obesity (DIO) is a major contributor to type II diabetes and micro-and macro-vascular complications leading to peripheral vascular disease (PVD). Metabolic abnormalities of induced pluripotent stem cell-derived endothelial cells (iPSC-ECs) from obese individuals could potentially limit their therapeutic efficacy for PVD. The aim of this study was to compare the function of iPSC-ECs from normal and DIO mice using comprehensive in vitro and in vivo assays.
Introduction
Obesity is a rapidly growing threat to global healthcare, with .1.5 billion adults overweight and 400 million of them considered obese. Increasing evidence indicates a high-caloric high-fat diet is a significant risk factor for causing deleterious effects on metabolism and heart function, and has been strongly linked to the progression of heart disease and type 2 diabetes. 1 -3 Dysglycaemia associated with obesity, insulin resistance and subsequent diabetes mellitus can lead to decreased nitric oxide (NO) bioavailability, endothelial nitric oxide synthase (eNOS) uncoupling, and increased levels of reactive oxygen species (ROS). 4 Left unchecked, this oxidative stress can result in an increased production of pro-inflammatory cytokines, leading to oxidative DNA damage and the activation of cellular apoptotic signals and pathways. 5, 6 The hallmark of endothelial dysfunction involved in obesity and its vascular complications is thought to be the result of interplay between apoptosis, inflammation, and oxidative stress, including a reduced bioavailability of NO. 7 Statins are 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors used primarily to lower cholesterol levels. Statins have also been shown to have beneficial effects on endothelial progenitor cells, improve endothelial function, increase NO production, augment neovascularization, and decrease ROS and inflammatory cytokines. 8 In recent years, embryonic stem cell-derived endothelial cells (ESC-ECs) have been evaluated in models of myocardial infarction and hindlimb ischaemia as a potential therapeutic option to promote angiogenesis and neovascularization. 9 -11 At present, therapies derived from ESCs are associated with significant ethical and political concerns. The recent discovery of induced pluripotent stem cells (iPSCs) has provided an alternative for the treatment of ischaemic vascular disease. 12 However, little is known about the function of induced pluripotent stem cell-derived endothelial cells (iPSC-ECs) derived from obese or overweight individuals, specifically whether they exhibit properties of endothelial dysfunction and impaired vascular function similar to native ECs from these individuals. This could potentially limit the use of iPSC-ECs from patients with diabetes as a therapeutic option for peripheral vascular disease (PVD) unless coadminister with low-dose pravastatin therapy.
Methods
An extended methods section is available in Supplementary material online.
Surgical model for hindlimb ischaemia and cell delivery
The surgical procedure for the induction of unilateral hindlimb ischaemia was performed following a previously published protocol. 13 Briefly, mice were anesthetized in an induction chamber containing 1-2% isoflurane (Baxter HealthCare, Deerfield, IL, USA) in 100% oxygen at a flow rate of 1 L/min. Ischaemia was induced by two separate ligations of the femoral artery, one distal and one proximal to the origin of the deep femoral branch. Subsequently, the skin was closed using 5-0 Vicryl sutures. Following the operation, animals were randomized into seven groups (n ¼ 10 per group) and each was administered a single gastrocnemius intramuscular (IM) injection containing: (i) 50 mL of 1 : 1 Matrigel/ EBM2 (vehicle), (ii) vehicle plus intraperitoneal (IP) pravastatin co-administration daily, (iii) 1 × 10 6 pooled iPSC-ECs from control donors in 50 mL of 1 : 1 Matrigel/EBM2, (iv) 1 × 10 6 pooled iPSC-ECs from DIO donors in 50 mL of 1 : 1 Matrigel/EBM2, (v) a single injection of 1 × 10 6 pooled iPSC-ECs from DIO donors plus co-administration of pravastatin (20 mg/kg body weight; injected volume, 0.02 mL/g body weight, IP), (vi) a single injection of 1 × 10 6 pooled iPSC-ECs from DIO donors pre-incubated with 1 mM pravastatin for 7 days, and (vii) a single injection of 1 × 10 6 pooled iPSC-ECs from DIO donors plus co-administration of pravastatin and NO synthase inhibitor N v -nitro-L-arginine methyl ester (L-NAME) daily. Prior to cell injection, iPSC-ECs were labelled with CellTracker CM-DiI cell-labelling solution (Life Technologies) according to the manufacturer's instructions so that the injected cells could be visualized post-mortem. 14 To inhibit NO synthesis, L-NAME was administered in the drinking water at a concentration of 1 mg/mL during days 1 through 14 post cell delivery. Laser Doppler imaging (LDI) was performed on Days 0, 3, 7, 10, and 14 following cell injection.
Statistical analysis
Statistics were calculated using GraphPad Prism (GraphPad Software, La Jolla, CA, USA). In vitro data were obtained from at least three independent experiments. Statistical significance between two groups was determined by paired or unpaired Student's t-test. For simple comparison between groups, one-way ANOVA was applied if the data were normally distributed, otherwise nonparametric Kruskal -Wallis test was used. For drug treatment experiments, two-way ANOVA followed by Bonferroni or Tukey's post hoc tests were applied. P-values were considered statistically significant if P , 0.05 and all actual P-value are shown in the figures. All data are expressed as mean + SD.
Results
Reprogramming of fibroblasts from control and diet-induced obesity mice into induced pluripotent stem cells
A previously published study has demonstrated that iPSCs can be generated from individuals with type 1 diabetes. 15 However, this study did not report the reprogramming efficiency of these cells. Hence, to test whether there is an inherent difference in the capacity of fibroblasts from control and DIO mice to be reprogrammed into iPSCs, tail tip fibroblasts were isolated from 24-week-old C57Bl/6 mice fed either a normal (10 kcal% from fat) or high-fat (60 kcal% from fat) diet beginning at 6 weeks of age. At 24 weeks of age, high-fat DIO mice had significantly increased body weight (P ¼ 0.001), fasting glucose (P ¼ 0.016), and showed a significant decrease in glucose and insulin tolerance compared to control mice (P , 0.0001; Supplementary material online, Figure S1A -D). Next, we successfully reprogrammed tail tip fibroblasts into murine iPSCs using a codon optimized 4-in-1 lentiviral vector encoding Oct-4, Klf4, Sox2, and c-Myc. On Day 15 after reprogramming, we mechanically dissociated the individual iPSC colonies and transferred them onto irradiated MEF feeder layers for clonal expansion into multiple cell lines (3 lines/mouse, 5 mice/group) ( Figure 1A ). All murine iPSC colonies stained positive for alkaline phosphatase, as well as pluripotency markers SSEA-1, Oct4, Sox2, and c-Myc ( Figure 1B -D) . Interestingly, reprogramming efficiency was significantly lower in iPSCs derived from DIO mice compared with those derived from control mice (P ¼ 0.003; Figure 1E ). Immunohistochemistry and real-time polymerase chain reaction (RT-PCR) confirmed that the established iPSC lines were able to form cells derived from all three germ layers in vitro, expressed markers specific for endoderm, ectoderm, and mesoderm (Supplementary material online, Figure S2A and B and Table S1 ), and also maintained a normal karyotype after extended passage (Supplementary material online, Figure S3A and B).
Control and diet-induced obesity induced pluripotent stem cells can be successfully differentiated into induced pluripotent stem cell-derived endothelial cells
Next, we successfully differentiated iPSCs (at passage 15) from control and DIO mice into iPSC-ECs via a chemically defined monolayer differentiation protocol ( Figure 2A ). On Day 10 after induction of differentiation, iPSC-ECs were stained using antibodies against CD31 and CD144 and subsequently sorted by FACS. Doublepositive (CD31 + /CD144 + ) cells were then plated on 0.2% gelatincoated plates for further expansion and characterization. Isolated iPSC-ECs showed Dil-Ac-LDL uptake and stained positive for endothelial markers CD31 and CD144 ( Figure 2B ). Flow cytometry showed no significant difference in EC differentiation capacity between iPSCs generated from DIO mice or healthy mice (18.80 + 1.51% vs. 20.47 + 1.75%, respectively; P ¼ 0.28) (Supplementary material online, Figure S4 ).
Diet-induced obesity induced pluripotent stem cell-derived endothelial cells exhibit endothelial dysfunction phenotype in vitro
Endothelial cells isolated from obese individuals have been shown to demonstrate properties of endothelial dysfunction in vitro. 16 Similarly, we found cell migration and proliferation were significantly reduced among both aortic-ECs (data not shown) and iPSC-ECs from DIO mice compared with aortic-ECs and iPSC-ECs from control mice (P , 0.05; Figure 3A , B and E). Additionally, iPSC-ECs from DIO but not control mice showed a significant increase in apoptosis when cultured in a hypoxic environment (P ¼ 0.007; Figure 3C and D). iPSC-ECs from DIO mice had significantly reduced capacity to form cord-like structures on Matrigel compared with control cells after 24 h (P , 0.001; Figure 3F ). Incubation of iPSC-ECs from DIO mice with 1 mM pravastatin for 24 h resulted in significant increases in cell migration (P , 0.001), proliferation (P ¼ 0.003), and number of cord-like structures on Matrigel (P , 0.001), and significant decrease The addition of 1 mM pravastatin to diet-induced obesity induced pluripotent stem cell-derived endothelial cells for 24 h resulted in significant increases in cell migration (P , 0.001), proliferation (P ¼ 0.003), and the number of cord-like structures (P , 0.001), while significantly decreasing endothelial cell apoptosis (P ¼ 0.019).
(G) Measurement of nitrite levels in cell culture supernatant by Griess reaction demonstrated that diet-induced obesity induced pluripotent stem cell-derived endothelial cells had significantly lower levels of nitric oxide production compared with control induced pluripotent stem cell-derived endothelial cells (P ¼ 0.019). Incubation of diet-induced obesity induced pluripotent stem cell-derived endothelial cells with 1 mM pravastatin for 24 h resulted in significantly higher levels of nitric oxide (P ¼ 0.016). The effect of pravastatin on nitrite levels in diet-induced obesity induced pluripotent stem cell-derived endothelial cell was blocked by co-incubation with N v -nitro-L-arginine methyl ester (P ¼ 0.001).
in apoptosis (P ¼ 0.019). Finally, DIO iPSC-ECs had significantly lower levels of NO production compared with control iPSC-ECs (P ¼ 0.019); incubation of DIO iPSC-ECs with 1 mM pravastatin for 24 h resulted in significantly higher levels of NO (P ¼ 0.016). However, the effect of pravastatin in DIO iPSC-ECs was blocked by co-incubation with the NO synthase inhibitor L-NAME (P ¼ 0.001) ( Figure 3G) . Interestingly, incubation of DIO iPSC-ECs with other statins including rosuvastatin (R-statin) and atorvastatin (A-statin) resulted in much less functional recovery compared with pravastatin (P-statin) (Supplementary material online, Figure S5 ), which might be due to their different pharmacokinetic properties. Pravastatin reverses obesity-induced dysfunction of induced Activation of Akt-endothelial nitric oxide synthase signalling pathway is suppressed in diet-induced obesity induced pluripotent stem cell-derived endothelial cells
As shown in Figure 3G , a hallmark of DIO iPSC-EC dysfunction was reduced NO production, which could be caused by reduced expression of endothelial or cytokine-inducible forms of NO synthase (eNOS and iNOS), impairment of eNOS activation, and/or increased eNOS uncoupling. 18, 19 Previous studies have shown that statins can rapidly promote the activation of Akt in endothelial cells leading to eNOS phosphorylation and increased NO production. 20 To address our hypothesis that Akt and eNOS activation by statins was involved in improvement of DIO iPSC-EC function, we assessed eNOS and iNOS gene expressions as well as protein levels in control iPSC-ECs, DIO iPSC-ECs, and DIO iPSC-ECs with pravastatin preincubation. We found that DIO iPSC-ECs had significantly lower eNOS expression compared with control iPSC-ECs, which was reversed by pravastatin treatment for 24 h (Supplementary material online, Figure S6A and B). Compared with eNOS expression, iNOS gene expression and protein levels were much lower in both control and DIO iPSC-ECs, suggesting a less important role in regulation of endothelial function (Supplementary material online, Figure S7 ). We next assessed the modulation of Akt phosphorylation, eNOS phosphorylation, and eNOS coupling status by western blot analysis. A previous study showed that PKC signalling in endothelial cells inhibits eNOS activity by phosphorylating Thr-495 and dephosphorylating Ser-1177, whereas PKA signalling acts in reverse by increasing phosphorylation of Ser-1177 and dephosphorylation of Thr-495 to activate eNOS. 21 We found that iPSC-ECs from DIO mice showed significantly decreased phospho-Akt and phosphorylation of eNOS at the Ser1177 residue, which was reversed by pravastatin treatment. In contrast, the phosphorylation of eNOS at the Thr495 residue in DIO iPSC-ECs was significantly increased compared with control iPSC-ECs, indicating the deactivation of eNOS is associated with DIO (Supplementary material online, Figure S6A , C-E). Finally, the percentage of the dimer-to-monomer ratio, an indicator of eNOS uncoupling which could lead to reduction of enzymatic activity, 22,23 also showed a significant decrease in DIO iPSC-ECs, and was increased by pravastatin treatment (Supplementary material online, Figure S6A , F).
Elevated apoptotic, inflammatory, and oxidative stress pathways in diet-induced obesity induced pluripotent stem cell-derived endothelial cells
Previous studies have shown endothelial dysfunction in patients with obesity is in part related to increased levels of oxidative stress, inflammation, cell apoptosis, and decreased NO production. 24 In order to investigate the mechanisms underlying the in vitro functional
Pravastatin reverses obesity-induced dysfunction of induced differences observed between DIO iPSC-ECs and control iPSC-ECs, we next performed microarray analysis. Our results indicate that 472 genes were differentially regulated in pathways related to apoptosis, inflammation, oxidative stress, and cellular senescence ( Figure 4A ; Supplementary material online, Figure S8 and Excel file). We performed RT-PCR on a panel of genes involved in apoptosis and oxidative stress in control iPSC-ECs, DIO iPSC-ECs, and DIO iPSC-ECs after 1 mM pravastatin treatment for 24 h. Of the genes investigated in these panels, 33 were significantly up-regulated (.three-fold) in DIO iPSC-ECs when compared with control iPSC-ECs ( Figure 4B ; Supplementary material online, Table S2A and B). After pravastatin treatment, 28 apoptotic and oxidative genes were down-regulated in DIO iPSC-ECs. We nextperformed ELISA assaystodeterminelevels of pro-and anti-inflammatory cytokines in cell culture supernatants following hypoxia for 24 h to mimic an ischaemic environment. Compared with control iPSC-ECs, DIO iPSC-ECs had significantly higher levels of inflammatory cytokines, including IL-1a, IL-1b, IL-4, IFN-g, and TNF-a. Similarly, incubation of DIO iPSC-ECs with 1 mM pravastatin for 24 h resulted in significant decreases in the pro-inflammatory cytokines IL-1a, IL-1b, IL-4, and TNF-a, as well as significant increases in the anti-inflammatory cytokines IL-6, IL-10, and IL-17A (Supplementary material online, Figure S9 ).
Dysfunction of diet-induced obesity induced pluripotent stem cell-derived endothelial cells in a hindlimb ischaemia model is reversed by pravastatin co-administration
Several groups have demonstrated that healthy iPSC-ECs are effective in promoting angiogenesis and neovascularization in a hindlimb ischaemia model. 25, 26 However, it is unknown if DIO iPSC-ECs will also function properly in vivo. To characterize the functional differences between iPSC-ECs from control and DIO mice, we next induced hindlimb ischaemia and used LDI to quantify perfusion. Mice were randomized into seven groups (n ¼ , and the level of perfusion was similar to that of mice receiving control iPSC-ECs. When mice that received DIO iPSC-ECs plus daily pravastatin also received the NO synthase inhibitor L-NAME in their drinking water, the increases in hindlimb reperfusion were significantly blunted from Day 7 onwards (0.62 + 0.02 vs. 0.54 + 0.09, DIO iPSC-ECs + IP statin vs. DIO iPSC-ECs + statin + L-NAME, P ¼ 0.004), suggesting that the effect of pravastatin was via an NO-dependent pathway. Finally, we found that starting at Day 7, mice that received DIO iPSC-ECs combined with pravastatin treatment (either systemic treatment or pre-incubation) showed better hindlimb reperfusion than mice receiving pravastatin alone (0. Histological evaluation of ischaemic hindlimbs confirms an apoptotic and inflammatory phenotype
We next performed histological evaluation of the ischaemic hindlimbs on Day 14 following cell injections. Hematoxylin & eosin (H&E) stained sections of hindlimbs from mice injected with DIO iPSC-ECs showed evidence of muscle atrophy and degeneration, as well as infiltration of inflammatory cells. In contrast, animals injected with control iPSC-ECs or DIO iPSC-ECs plus daily IP injections of pravastatin were protected from this damage. Animals injected with pre-treated DIO iPSC-ECs also showed reduced infiltration of neutrophils; however, the difference between DIO iPSC-ECs and DIO iPSC-ECs pre-treated with pravastatin did not reach statistical significance (P ¼ 0.112) ( Figure 6A and C ). Immunostaining revealed that CD31 + capillary density was significantly lower in the hindlimbs of mice injected with DIO iPSC-ECs compared with control iPSC-ECs (P ¼ 0.006) ( Figure 6B and D) . Increased CD31 + capillary density was observed in mice injected with DIO iPSC-ECs plus daily IP injections of pravastatin compared with mice injected with DIO iPSC-ECs alone (P ¼ 0.047). Co-administration of the NO synthase inhibitor L-NAME with pravastatin blocked this effect (P ¼ 0.001). Moreover, there was a trend showing that injection of DIO iPSC-ECs pre-treated with pravastatin for 7 days could also increase the capillary density compared with injection of untreated DIO iPSC-ECs; however, this did not reach statistical significance (P ¼ 0.064). Immunofluorescent staining for CM-DiI-labelled iPSC-ECs verified engraftment of control iPSC-ECs in the ischaemic hindlimbs at Day 14 (Supplementary material online, Figure S10 ). There was less detectable fluorescent signal in sectioned ischaemic hindlimbs of mice injected with labelled DIO iPSC-ECs compared with mice injected with DIO iPSC-ECs combined with daily IP injections of pravastatin.
Discussion
Following hindlimb ischaemia injury, transplantation of ESC-ECs or iPSC-ECs can result in their incorporation into the host vasculature and increase reperfusion. 9, 10, 27 However, since cells used in these studies were derived from healthy donors, it remains unknown if iPSC-ECs derived from DIO donors will function in the same way.
Since patients who will require intervention to restore normal perfusion are likely to have significant morbidity such as obesity, identifying, and reversing endothelial dysfunction would be important before future application in regenerative medicine. The current study is the first to compare the functional capacity of iPSC-ECs from control healthy mice vs. DIO mice in vitro and in vivo. We first showed that DIO iPSC-ECs had impaired function in vitro compared with control iPSC-ECs. DIO iPSC-ECs had a reduced capacity to form cord-like structures on Matrigel after 24 h, as well as decreased migration and proliferation in vitro. When cultured in hypoxic conditions, DIO iPSC-ECs showed an increase in apoptosis compared with control iPSC-ECs. Second, by using a murine hindlimb ischaemia model, we showed that DIO iPSC-ECs exhibit impaired vascular function in vivo. Mice injected with DIO iPSC-ECs achieved significantly less reperfusion beginning at Day 10 compared with mice injected with control iPSC-ECs. While inflammation is often observed following surgical induction of hindlimb ischaemia, 28 we observed significantly more inflammatory cells as well as muscle atrophy in mice injected with DIO iPSC-ECs compared with those injected with control iPSC-ECs. Immunostaining for CD31
+ cells also revealed significantly lower capillary density counts in the hindlimbs of mice injected with DIO iPSC-ECs compared with control iPSC-ECs. Microarray gene expression analysis comparing iPSC-ECs from control and DIO mice revealed 472 differentially regulated genes involved in biological pathways, including apoptosis, inflammation, immune function, oxidative stress, and cell senescence. Previous studies have demonstrated that statin treatment can promote angiogenesis in murine models of hindlimb ischaemia. 20, 29 In addition to their lipid lowering effects, statins can decrease inflammation and increase eNOS expression, resulting in a subsequent increase in NO bioavailability. 30 -33 In keeping with these observations, another important finding of this study is that co-administration of low-dose pravastatin is able to reverse much of the dysfunction observed with DIO iPSC-ECs both in vitro and in vivo. Mechanistically, pravastatin therapy had significant beneficial effects in vitro on apoptosis, inflammation, and oxidative stress in DIO iPSC-ECs (Supplementary material online, Figure S11 ). Pravastatin also resulted in a significant improvement in hindlimb reperfusion following ischaemia compared with mice receiving iPSC-ECs without pravastatin co-administration. These effects were inhibited by concurrent administration of L-NAME, an NO synthase inhibitor, suggesting the effects of pravastatin were via an NO-dependent mechanism. Taken together, these results correlate with a large body of evidence demonstrating that in pre-diabetes and DIO, abnormally high levels of inflammatory and oxidative stress biomarkers are associated with increased cellular apoptosis, leading to subsequent long-term complications such as endothelial dysfunction. 34 These prolonged periods of heightened oxidative stress and inflammation can result in dysfunctional progenitor and stem cell populations, which have been implicated in increased risk of cardiovascular disease and PVD in patients with diabetes. 35, 36 The observation that DIO iPSC-ECs show impaired function both in vitro and in vivo suggests one of the consequences of the altered metabolic state is the induction of global epigenetic changes that contribute to impaired EC function seen in these animals. These results are relevant and significant for cell therapy approaches. While autologous iPSC-ECs derived from obese patients might obviate issues associated with immunological rejection, these iPSC-ECs may be inadequate for restoring normal vascular function compared with iPSC-ECs derived from healthy donors. Based on these results, low-dose statin therapy may be a useful adjuvant when co-administered with dysfunctional DIO iPSC-ECs. Finally, the current iPSC-EC platform can also be used to identify additional novel drug targets that can alter the diabetes-induced dysfunctional state. 37 In summary, our study is the first to show that iPSC-ECs derived from DIO mice exhibit decreased vascular function in vitro, and reduced function and incorporation into the host vasculature in vivo. Histological evaluation revealed muscle atrophy and increased infiltration of inflammatory cells in the ischaemic hindlimbs of mice receiving DIO iPSC-ECs. The EC dysfunction may be related to apoptosis, inflammation, and oxidative stress due to decreased NO production. Co-administration with low-dose pravastatin therapy reversed EC dysfunction both in vitro and in vivo. Collectively, these findings may have important implications and caveats for future patient-specific iPSC-EC therapy, especially in pre-diabetic or DIO patients with PVD.
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